Key facts
- It has raised $45.8M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Apr 2023.
- Notable investors include MassChallenge, MedTech Innovator, The JHA Capital, Beacon Angels, Greyhill Ventures — 18 tracked in total.
- RevBio has filed 5 Form Ds with the SEC since 2021, most recently Jul 2025 ($10.0M sold to 54 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for RevBio
Funding rounds
2 roundsAbout RevBio
Developer of regenerative adhesive biomaterial, designed to facilitate bone repair and regeneration in medical procedures. The company offers an injectable, biocompatible material that adheres to wet bone, promotes new bone growth, and resorbs over time, enabling dental and orthopedic specialists with stable fixation and support for natural healing.
- Sector
- Healthcare
- HQ
- Lowell, MA, United States
- Founded
- 2014
- Employees
- 33
- Website
- revbio.com/
- Ownership
- Privately Held (backing)
RevBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RevBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RevBio in its N-PORT filings yet. We sweep new filings monthly.